Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 921-930

  Scarpero, Harriette ^a   Sand, Peter K ^b   Kelleher, Con J ^c   Berriman, Sandra ^d   Bavendam, Tamara ^d   Carlsson, Martin ^d  

^a Associated Urologists   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d PFIZER INC   (United States)

Author keywords

Efficacy; Fesoterodine; Health related quality of life; Overactive bladder; Safety; Tolerability

Indexed keywords

FESOTERODINE;

ADULT; ARTICLE; BACKACHE; CONSTIPATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OSTEOARTHRITIS; OVERACTIVE BLADDER; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; XEROSTOMIA;

ADULT; AGED; BENZHYDRYL COMPOUNDS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; URINARY BLADDER, OVERACTIVE;

EID: 79954536516     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.559581     Document Type: Article

References (27)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78. (Pubitemid 34195211)
2. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20.
3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15. (Pubitemid 44692945)
4. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6. (Pubitemid 34204313)
5. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36. (Pubitemid 44175300)
6. Irwin DE, Abrams P, Milsom I, et al. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 2008;101:1381-7. (Pubitemid 351623987)
7. Irwin DE, Milsom I, Kopp Z, et al. Symptom bother and health careseeking behavior among individuals with overactive bladder. Eur Urol 2008; 53:1029-37.
8. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94.
9. Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 2009;65:309-14.
10. Gopal M, Haynes K, Bellamy SL, et al. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008;112:1311-18.
11. Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008;102:774-9.
12. Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276-82.
13. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008;9:1787-96.
14. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12. (Pubitemid 47332062)
15. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94. (Pubitemid 350052177)
16. Herschorn S, Jones JS, Oelke M, et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 Phase III studies. Urology 2010;75:1149-55.
17. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008;71:839-43.
18. Sand PK, Morrow JD, Bavendam T, et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:827-35.
19. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-tohead placebo-controlled trial. BJU Int 2010;105:58-66.
20. Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. Epub ahead of print; DOI: 10.1111/ j.1464-410X.2010.09640.x.
21. Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008;102:1128-32.
22. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and metaanalysis. Eur Urol 2008;54:543-62.
23. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 2006;98:1025-32. (Pubitemid 44536453)
24. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376-84. (Pubitemid 40248865)
25. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001;18:551-60. (Pubitemid 32664728)
26. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, communitybased, randomized study. BJU Int 2007;99:836-44. (Pubitemid 46439555)
27. Lee S, Malhotra B, Creanga D, et al. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol 2009;9:55